XML 73 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Liquidity and Going Concern (Details) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Oct. 17, 2022
Sep. 28, 2022
Feb. 28, 2022
Apr. 30, 2021
Sep. 30, 2020
Liquidity And Going Concern [Line Items]                      
Net working capital   $ 219,600,000   $ 146,400,000              
Cash and cash equivalents   2,483,000   4,338,000 $ 4,839,000 $ 10,295,000          
Operating loss   30,893,000 $ 25,421,000 35,838,000 35,258,000 138,695,000          
Cash flow from operation   20,533,000 $ 22,707,000 28,664,000 31,461,000 60,421,000          
Retained earnings accumulated deficit   358,030,000   352,550,000 264,126,000            
Debt Instrument, Annual Principal Payment       45,900,000 $ 69,800,000 $ 2,300,000          
Minimum net worth to consummate business combination             $ 5,000,001        
Funding Commitment Letter [Member]                      
Liquidity And Going Concern [Line Items]                      
Line of Credit Facility, Maximum Borrowing Capacity             10,000,000        
Aggregate Outstanding Amount             310,000,000        
Scilex Pharma Notes [Member]                      
Liquidity And Going Concern [Line Items]                      
Debt Instrument, Annual Principal Payment   41,400,000                  
Debt instrument, decrease, forgiveness   $ 28,000,000                  
Notes Payable, Related Parties               $ 34,000,000      
Subsequent Event [Member]                      
Liquidity And Going Concern [Line Items]                      
Minimum net worth to consummate business combination             5,000,001        
Subsequent Event [Member] | Funding Commitment Letter [Member]                      
Liquidity And Going Concern [Line Items]                      
Line of Credit Facility, Maximum Borrowing Capacity             10,000,000        
Aggregate Outstanding Amount             $ 310,000,000        
Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member]                      
Liquidity And Going Concern [Line Items]                      
Debt instrument face amount $ 224,000,000                    
Proceeds from senior secured notes 140,000,000                    
Minimum unrestricted cash balance $ 4,000,000                    
Debt instrument face amount of debt repurchased                   $ 40,000,000 $ 65,000,000
Restricted funds releasable for future repurchase of debt                     $ 45,000,000
Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member] | Cumulative Sales Related Contingency [Member]                      
Liquidity And Going Concern [Line Items]                      
Debt instrument face amount       $ 28,000,000              
Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member] | Letter Of Credit Drawn Down [Member] | Subsequent Event [Member]                      
Liquidity And Going Concern [Line Items]                      
Minimum unrestricted cash balance                 $ 10,000,000    
Debt instrument repurchase obligation                 $ 20,000,000